Goldman Sachs Group Inc Xenon Pharmaceuticals Inc. Transaction History

Goldman Sachs Group Inc

  • $605 Billion
  • Q3 2024

A detailed history of Goldman Sachs Group Inc transactions in Xenon Pharmaceuticals Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 459,625 shares of XENE stock, worth $18.3 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
459,625
Previous 364,173 26.21%
Holding current value
$18.3 Million
Previous $14.2 Million 27.38%
% of portfolio
0.0%
Previous 0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
BUY
$36.12 - $43.96 $3.45 Million - $4.2 Million
95,452 Added 26.21%
459,625 $18.1 Million
Q2 2024

Aug 13, 2024
BUY
$36.25 - $43.75 $2.33 Million - $2.82 Million
64,399 Added 21.48%
364,173 $14.2 Million
Q1 2024

May 15, 2024
SELL
$42.66 - $50.04 $3.26 Million - $3.83 Million
-76,528 Reduced 20.34%
299,774 $12.9 Million
Q4 2023

Feb 13, 2024
BUY
$28.7 - $46.46 $3.47 Million - $5.62 Million
120,934 Added 47.36%
376,302 $17.3 Million
Q3 2023

May 14, 2024
SELL
$34.16 - $39.73 $4.13 Million - $4.8 Million
-120,934 Reduced 32.14%
255,368 $8.72 Million
Q3 2023

Nov 14, 2023
SELL
$34.16 - $39.73 $673,361 - $783,157
-19,712 Reduced 7.17%
255,368 $8.72 Million
Q2 2023

May 14, 2024
SELL
$34.84 - $43.54 $360,350 - $450,334
-10,343 Reduced 3.62%
275,080 $10.6 Million
Q2 2023

Aug 14, 2023
SELL
$34.84 - $43.54 $360,350 - $450,334
-10,343 Reduced 3.62%
275,080 $10.6 Million
Q1 2023

May 14, 2024
BUY
$33.46 - $40.35 $62,971 - $75,938
1,882 Added 0.66%
285,423 $10.2 Million
Q1 2023

May 11, 2023
BUY
$33.46 - $40.35 $62,971 - $75,938
1,882 Added 0.66%
285,423 $10.2 Million
Q4 2022

May 14, 2024
SELL
$33.06 - $39.43 $6.01 Million - $7.17 Million
-181,724 Reduced 39.06%
283,541 $11.2 Million
Q4 2022

Feb 13, 2023
SELL
$33.06 - $39.43 $6.01 Million - $7.17 Million
-181,724 Reduced 39.06%
283,541 $11.2 Million
Q3 2022

May 14, 2024
BUY
$30.79 - $39.82 $5.2 Million - $6.73 Million
168,951 Added 57.02%
465,265 $16.8 Million
Q3 2022

Nov 10, 2022
BUY
$30.79 - $39.82 $5.2 Million - $6.73 Million
168,951 Added 57.02%
465,265 $16.8 Million
Q2 2022

May 14, 2024
SELL
$25.44 - $35.16 $2.03 Million - $2.81 Million
-79,988 Reduced 21.26%
296,314 $9.01 Million
Q2 2022

Aug 15, 2022
SELL
$25.44 - $35.16 $10.9 Million - $15 Million
-428,023 Reduced 59.09%
296,314 $9.01 Million
Q1 2022

May 16, 2022
BUY
$25.09 - $33.13 $13.9 Million - $18.3 Million
552,943 Added 322.62%
724,337 $22.1 Million
Q4 2021

Feb 14, 2022
BUY
$15.6 - $35.4 $1.18 Million - $2.67 Million
75,409 Added 78.56%
171,394 $5.35 Million
Q3 2021

Nov 10, 2021
BUY
$14.86 - $19.45 $1.43 Million - $1.87 Million
95,985 New
95,985 $1.47 Million

Others Institutions Holding XENE

# of Institutions
212
Shares Held
70.2M
Call Options Held
88.3K
Put Options Held
28.8K
View Full List

About Xenon Pharmaceuticals Inc.

XENE Quotes by TradingView
  • Ticker XENE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 62,263,500
  • Market Cap $2.48B
  • Description
  • Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopath...
More about XENE
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email